Alnylam Pharmaceuticals
ALNY
210 hedge funds and large institutions have $2.99B invested in Alnylam Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 72 reducing their positions, and 77 closing their positions.
93.15% more ownership
Funds ownership: 0% → 93.15% (+93%)
6% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 72
8% less call options, than puts
Call options by funds: $34.4M | Put options by funds: $37.3M
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
19% less funds holding
Funds holding: 258 → 210 (-48)
43% less capital invested
Capital invested by funds: $5.24B → $2.99B (-$2.25B)
53% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 77
Top Buyers
| 1 |
Dodge & Cox
San Francisco,
California
|
+$164M |
| 2 |
SPC
Slate Path Capital
New York
|
+$32.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$14.4M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$13.3M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$12.6M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$53M |
| 2 |
AWG
Alpha Wave Global
New York
|
-$33.3M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$18.4M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$18.3M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$15M |
ALNY Hedge Fund Activity: Q4 2016 in Review
210 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2016, worth a combined $2.99B — down 43% from $5.24B a quarter earlier.
Sellers outnumbered buyers: 77 funds closed out of ALNY and 36 opened new positions — a net loss of 41 holders — while 72 trimmed existing stakes and 76 added.
The largest buyer was Dodge & Cox, adding an estimated $164M. The largest seller was Jennison Associates, exiting entirely with an estimated $53M sold.
- 210 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2016, down from 258 in Q3 2016.
- Funds reported $2.99B of Alnylam Pharmaceuticals stock for Q4 2016, down 43% quarter-over-quarter.
- 36 funds opened new Alnylam Pharmaceuticals positions in Q4 2016 and 77 closed out, a net change of -41 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2016 was Dodge & Cox, an estimated $164M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2016 was Jennison Associates, an estimated $53M sold.
Based on aggregated 13F filings for Q4 2016.